Patents Assigned to Lentigen Technology Inc.
  • Method to treat cancer with engineered T-cells
    Patent number: 12193995
    Abstract: Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 14, 2025
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Boro Dropulic, Rimas J. Orentas, Dina Schneider, Winfried Krueger
  • Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
    Patent number: 12122831
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: October 22, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Compositions and methods for treating cancer with anti-CD123 immunotherapy
    Patent number: 12037403
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: July 16, 2024
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating HIV/AIDS with immunotherapy
    Patent number: 12024554
    Abstract: Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: July 2, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Kim Anthony Gonda, Dina Schneider, Rimas Orentas, Boro Dropulic
  • Compositions and methods for treating cancer with self-driving chimeric antigen receptors
    Patent number: 11969443
    Abstract: Self-driving surface antigen-regulated promoter-therapeutic payload constructs containing antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the surface antigen-regulated promoter-therapeutic payload constructs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making self-driving surface antigen-regulated promoter-therapeutic payload constructs in T-cells are also disclosed.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: April 30, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Boro Dropulic, Brian Robert Webster
  • Compositions and methods for treating cancer with anti-mesothelin immunotherapy
    Patent number: 11970528
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: April 30, 2024
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Chimeric antigen receptors and methods of use
    Patent number: 11905515
    Abstract: Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: February 20, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD22 immunotherapy
    Patent number: 11878052
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: January 23, 2024
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 11802142
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: October 31, 2023
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD19 immunotherapy
    Patent number: 11708408
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: July 25, 2023
    Assignees: Lentigen Technology Inc., The U.S.A. as represented by the Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
    Patent number: 11680103
    Abstract: Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: June 20, 2023
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Boro Dropulic, Dina Schneider
  • Compositions and methods for treating cancer with anti-CD123 immunotherapy
    Patent number: 11590169
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: February 28, 2023
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Zhongyu Zhu, Florian Tomszak, Rafijul Bari
  • Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
    Patent number: 11497770
    Abstract: Chimeric antigen receptors containing TSLPR-CD19 and TSLPR-CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: November 15, 2022
    Assignees: Lentigen Technology, Inc., The Regemts of the University of Colorado
    Inventors: Dina Schneider, Boro Dropulic, Terry James Fry
  • Compositions and methods for treating cancer with anti-CD33 immunotherapy
    Patent number: 11464801
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 11, 2022
    Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-ROR1 immunotherapy
    Patent number: 11453719
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: September 27, 2022
    Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 11453712
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 27, 2022
    Assignee: Lentigen Technology Inc.
    Inventors: Rimas Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
    Patent number: 11242389
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: February 8, 2022
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 11208455
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: December 28, 2021
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD38 immunotherapy
    Patent number: 11103533
    Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 31, 2021
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-BCMA immunotherapy
    Patent number: 11052112
    Abstract: Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: July 6, 2021
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Zhongyu Zhu, Boro Dropulic, Bang Khoa Vu, Leah Marie Alabanza